EMA Authorised: Tabrecta (capmatinib dihydrochloride monohydrate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Tabrecta (capmatinib dihydrochloride monohydrate) for non-small cell lung cancer. Novartis Europharm Limited is the marketing authorisation h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Novartis Europharm Limited. Decision date: 26/08/2025